AbbVie reports Phase 3 INTREPID trial meets primary and secondary endpoints for lutikizumab in hidradenitis suppurativa

AbbVie announced that its investigational IL‑1α/β antagonist lutikizumab achieved the primary endpoint of a 75% reduction in hidradenitis suppurativa lesions (HiSCR75) in 31.4% of patients versus 23.4% on placebo. The drug also lowered flare incidence to 18.4% versus 28.1% on placebo and improved skin‑pain scores, with a safety profile comparable to placebo. AbbVie said the data will support regulatory filings in the second half of 2027 and that lutikazumab will be evaluated in combination with its weight‑loss candidate ABBV‑295 and other pipeline assets.

The company expects the results to underpin a regulatory submission for lutikizumab in 2027, potentially adding a new therapy to its immunology portfolio. Analysts noted that the response rate was below market expectations, which could temper commercial upside.

  • 131.4% of lutikizumab‑treated patients achieved HiSCR75 at Week 16 versus 23.4% on placebo (p≤0.001).
  • 218.4% of lutikizumab patients experienced HS flares compared with 28.1% of placebo patients.
  • 3Treatment‑emergent adverse event rates were similar between groups (any AE 53.4% vs 53.7%; serious AE 3.0% vs 2.9%; discontinuations 1.7% vs 1.9%).
  • 4AbbVie plans to file regulatory submissions for lutikizumab in the second half of 2027.
  • 5The company will evaluate lutikizumab in combination with ABBV‑295 and potentially ABBV‑701 later in the year.

Sources